AzTrials
AzTrials

Type 1 DiabetesNCT04646473

Sweetgoals for Type 1 Diabetes

A study testing Coaching, Incentives and Sweetgoals app in people with Type 1 Diabetes, run by Trustees of Dartmouth College at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study will test an app and web-delivered intervention designed to improve glycemic control (HbA1c) among young adults with Type 1 diabetes. All participants will receive the "core" digital intervention, the SweetGoals app, focused on self-monitoring and goal setting. Read more about this study

Who is it for?
Ages 19 to 29 years
Conditions the study is for
Type 1 Diabetes
What is being tested?
Coaching, Incentives and Sweetgoals app
Could I receive a placebo?
No, everyone receives an active treatment
How many people
300 participants
Where
1 siteUnited States
Study dates
25 Jul 2021to 30 Apr 2025
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 to 29 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Have a diagnosis of T1D for >18 months
  • Have A1c ≥7.5%
  • Report a visit with physician managing type 1 diabetes (T1D) within the previous 6 months
  • Participants must use a glucometer or continuous glucose monitor compatible with Glooko.

Who cannot join

  • Pregnancy or breast feeding
  • Severe medical illness that would preclude participation (e.g., cystic fibrosis, developmental disability, severe cognitive impairment)
  • Psychiatric illness that would preclude participation
  • Diabetes diagnoses other than T1D (Type 2 Diabetes, Maturity Onset Diabetes of the Young/MODY)
  • Use of any medications known to impact glycemic control (oral or injectable corticosteroids, beta-blockers, antipsychotic medications such as risperidone).
  • A history of known hemoglobinopathy, anemia, or transfusion (which could alter the validity of HbA1c measurement)
  • Already being engaged in a psychological intervention targeting diabetes adherence.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Dartmouth College

    Hanover, New Hampshire, 03755

Other trials in United States

About this study

Official title: Thinking Outside the Clinic: A Digital Health Approach for Young Adults With Type 1 Diabetes

The study will test an app and web-delivered intervention designed to improve glycemic control (HbA1c) among young adults with Type 1 diabetes. All participants will receive the "core" digital intervention, the SweetGoals app, focused on self-monitoring and goal setting. Efficacy of two independent intervention components (incentives for adherence and web health coaching) will be tested

Read the detailed description

ASSIGNMENT OF PARTICIPANTS:

Interested participants will download the SweetGoals app. Once all screening procedures are complete, including A1c verification via the mail in test kit, research staff will schedule a web video meeting to (1) randomize participants and inform them of their intervention condition assignment; (2)assist participants in setting up their Glooko account and uploading their devices and orient them to the Glooko data visualization hub; and (3) download the Glooko mobile app, which may be used by all participants and into which participants without a Glooko compatible pump will enter carb counts.

INTERVENTION DELIVERY:

All participants will receive the core intervention, the SweetGoals app. Those assigned to Incentives will receive the app plus incentives for meeting adherence goals. Those assigned to Coaching will receive web health coaching to increase motivation and skill in self-management as described below.

DIABETES CARE FOR ALL PARTICIPANTS:

Participants in all conditions will receive ongoing treatment for type 1 diabetes from their current medical provider. Report of a visit within the past 6 months is a study inclusion criterion. Study staff will not provide medical care or intervention. All participants will receive information about recommendations for medical care related to diabetes (e.g., quarterly visits and A1c assessment, consistent with Standards of Medical Care in Diabetes). Informational links will be provided within SweetGoals for various online resources addressing T1D educational topics.

CORE INTERVENTION FOR ALL PARTICIPANTS: SWEETGOALS APP

All participants will receive the SweetGoals app, an automated intervention that sets weekly self-management goals and provides weekly feedback. The SweetGoals app will be implemented and delivered using the MobileCoach app platform, which runs on both Android and iOS systems. The SweetGoals app sends weekly reminders to upload devices, retrieves device data via the Glooko API, applies decision rules to evaluate daily and weekly goals, and sends weekly feedback messages about goal adherence and encouragement about adherence in the upcoming week.

Diabetes Self-Management Goals. Glooko stores multiple variables that are used to evaluate the glucose monitoring and mealtime goals. Across both glucose monitoring and mealtime target behaviors, we use a similar structure to the goals to promote ease of remembering the goals and communication with participants. Specifically, regardless of the devices used or the target (glucose monitoring or mealtime behaviors) there is a daily adherence goal, and there is a weekly goal of meeting the daily goal on >5 days each week. These weekly goals were selected to promote high consistency in mealtime glucose monitoring and carb counting. Each week, participants will be asked to set personal goals for the next week for the number of days they think they can meet each daily goal. Each week they will receive a message stating the number of days on which they met each goal, how that compared to their personal goal, and whether they met the ultimate weekly goal (met daily goal >5 days per week).

Glucose monitoring goals. Each participant will receive a device-specific (glucometer vs. CGM) daily goal based on the device they use to monitoring their glucose levels, and the ultimate weekly goal for all participants is to meet the daily goal on at least 5 days per week. For participants who use a glucometer only, the daily self-monitoring of blood glucose (SMBG) goal is >5 checks, each >2 hours from another check. For participants who use CGM, the CGM wear time goal is 80% of expected values each day. Expected values per day are based on the device-specific check frequency (e.g., every 5 mins for Dexcom G6). We selected this cutoff to reflect clinically necessary glucose monitoring frequency, but also allow for legitimate disconnect time (sports, leisure activities) and sensor changes.

Mealtime goals. Each participant will receive daily goals specific to their insulin delivery method (pump vs. MDI). Participants will be asked to check their glucose before they eat (if they use a glucometer only, not CGM). Participants who use a Glooko compatible pump will only need to use their pump to document the mealtime goals. If they use a pump+glucometer combination that requires manual entry of the glucose value into the pump, they must complete the glucose check and that manual entry no longer than 30 minutes before the carb entry to receive credit for meeting the mealtime goal. If they use a pump+CGM or other meter that transfers the glucose value to the pump without manual entry, no manual entry is necessary. If they use MDI (no insulin pump), they will use the Food event screen to enter their carb counts in the Glooko smartphone app.

When each participant's Glooko data are retrieved, our algorithm evaluates whether or not there is a valid glucose value within 30 minutes prior to each carb entry. The daily mealtime target is 3 paired glucose level/carb count values.

INCENTIVE COMPONENT

In addition to using the SweetGoals app, participants assigned to Incentives will also receive incentives for meeting goals. Incentives to improve adherence to glucose monitoring and mealtime behaviors that support appropriate insulin bolusing are paid weekly from weeks 1-11, then fade in frequency from weeks 12-25, a procedure used to promote long lasting improvements in adherence and A1c. In the fading phase, incentives are paid at increasing time intervals (i.e., 2,3,4 then 5-week delays; paid at weeks 13, 16, 20, 25).

For meeting daily and weekly goals, participants can earn the following incentives: (1) $1 for each day meeting glucose monitoring goal. (maximum=$7 per week); (2) $5 per week bonus for meeting the glucose monitoring goal 6 or 7 days to promote consistent weekly glucose monitoring. (maximum=$5 per week) (3) $1 for every day with >3 properly timed glucose value/carb entry pairs (maximum=$7 per week); (4) $5 per week bonus for meeting the mealtime goal 6 or 7 days to promote consistent weekly glucose checking and carb counting at mealtime. (maximum=$5 per week). Total earnings possible each week are $24 (~$3.50 per day). The maximum earnings for all goals are $600 across 25 weeks. Research staff will load earned incentives on reloadable prepaid MasterCards.

WEB HEALTH COACHING COMPONENT:

Participants assigned to coaching will also receive 15 Web Health Coaching sessions by a bachelors-level health coach. These coaching sessions are designed to promote effective self-management of diabetes. Coaching sessions are held weekly from weeks 1-11, then fade over the second half of the intervention with 4 sessions held during weeks 12-25 (weeks 13, 16, 20, and 25). Sessions 1-7 are 30 minutes each, as new material is introduced and practiced. Sessions 8-15 are 15 minutes each, as problem solving skills are practiced and applied to new challenges identified by participants. Coaching will be completed using Zoom, an online HIPAA compliant web conference system.

Conditions
Type 1 Diabetes
Being tested
Coaching, Incentives, Sweetgoals app
Medical subject headings
Diabetes Mellitus, Type 1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CoachingBehavioural

    Web health coaching

  • IncentivesBehavioural

    Financial incentives for meeting goals

  • Sweetgoals appBehavioural

    App provides weekly feedback about behavioral goals

Study groups in NCT04646473
Study groupRoleWhat they receive
Sweetgoals appExperimentalNot described
Receives: Behavioral: Sweetgoals app
Sweetgoals app, incentivesExperimentalNot described
Receives: Behavioral: Incentives; Behavioral: Sweetgoals app
Sweetgoals app, coachingExperimentalNot described
Receives: Behavioral: Coaching; Behavioral: Sweetgoals app
Sweetgoals app, incentives, coachingExperimentalNot described
Receives: Behavioral: Coaching; Behavioral: Incentives; Behavioral: Sweetgoals app

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percent Glycated Hemoglobin/6 Months

    Estimated mean change (slope) in percent glycated hemoglobin per each 6 month interval from Baseline to Month 12 were obtained from a growth curve analysis using maximum likelihood estimation to account for missing data. All randomized participants were utilized in the model (ITT analysis).

    Measured: From Baseline to Month 12

  2. Change in Hba1c at 12 Months, Main Effects of Each Intervention Component

    Estimated mean change from Baseline to Month 12 were obtained from a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the change in HbA1c at 12 months vs. baseline associated with the On level of the intervention condition relative to the Off level of the intervention condition.

    Measured: 12 months, controlling for baseline

Secondary outcomes (6)
  1. Change in Percent Glycated Hemoglobin Per Day of Glucose Checking Goal Achievement

    Estimated mean change from baseline to Month 12 was obtained from a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the change in HbA1c at 12 months from baseline associated with each additional day of glucose checking goal achievement during the 6-month intervention period.

    Measured: At 12 months, controlling for baseline

  2. Change in Percent Glycated Hemoglobin Per Day of Mealtime Goal Achievement

    Estimated mean change from baseline to Month 12 was obtained from a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the change in HbA1c at 12 months from baseline associated with each additional day of mealtime goal achievement during the 6-month intervention period.

    Measured: At 12 months, controlling for baseline

  3. Days Per Week Meeting Glucose Checking Goal During Intervention Period, Main Effects of Each Intervention Component

    Estimated mean days per week meeting checking goal were obtained from a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the difference in the mean days per week the checking goal was met associated with the On level of each intervention condition relative to the Off level of the intervention condition.

    Measured: Baseline to 6 months

  4. Days Per Week Meeting Mealtime Goal During Intervention Period, Main Effects of Each Intervention Component

    Estimated mean days per week meeting mealtime goal were obtained from a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the difference in the mean days per week the goal was met associated with the On level of each intervention condition relative to the Off level of the intervention condition.

    Measured: Baseline to 6 months

  5. Change in Percent Glycated Hemoglobin Due to Each Intervention Mediated by Days Met Glucose Checking Goal

    Estimated mean change from Baseline to12 months were obtained from a a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the change in HbA1c at 12 months resulting from the impact of the On level of each intervention condition relative to the Off level of the intervention condition as mediated by the mean days per week the glucose checking goal was met.

    Measured: Baseline to 12 months

  6. Change in Percent Glycated Hemoglobin Due to Each Intervention Mediated by Days Met Mealtime Goal

    Estimated mean change from Baseline to12 months were obtained from a a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the change in HbA1c at 12 months resulting from the impact of the On level of each intervention condition relative to the Off level of the intervention condition as mediated by the mean days per week the mealtime goal was met.

    Measured: Baseline to 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Nov 2020
  2. Study start25 Jul 2021
  3. Primary completion30 Apr 2025
  4. Study completion30 Apr 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Factorial
Model description
Optimization study. Main effects of each intervention condition are the primary aims.
Masking
None (open label)
Enrolment
300 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04646473
Sponsor's protocol ID
23559
Other IDs
R01DK124428
Status last verified
Jul 2026
First submitted
16 Nov 2020
Last updated
13 Aug 2026
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be made available to other researchers and practitioners, while safeguarding the privacy of participants and protecting confidential and proprietary data and third-party intellectual property. Findings will be published as soon as they are available in relevant peer-reviewed journals that are available online, and share as requested directly to the author(s). Data requests can be made directly to the Principal Investigator with information for accessing the data on the NIDDK Data Repository.

Publications

  • Yallampalli H, Plaitano EG, Stanger C. Technology readiness associated with insulin pump and automated insulin delivery system use in young adults with type 1 diabetes. J Health Psychol. 2026 Mar 29:13591053261433230. doi: 10.1177/13591053261433230. Online ahead of print.

    PubMed 41906546
  • Plaitano EG, Stanger C. Joint effect of nicotine use and diabetes distress on glycemic control in young adults with type 1 diabetes. J Diabetes Complications. 2025 Aug;39(8):109083. doi: 10.1016/j.jdiacomp.2025.109083. Epub 2025 May 17.

    PubMed 40398346
  • Stanger C, Kowatsch T, Xie H, Nahum-Shani I, Lim-Liberty F, Anderson M, Santhanam P, Kaden S, Rosenberg B. A Digital Health Intervention (SweetGoals) for Young Adults With Type 1 Diabetes: Protocol for a Factorial Randomized Trial. JMIR Res Protoc. 2021 Feb 23;10(2):e27109. doi: 10.2196/27109.

    PubMed 33620330

Questions about this trial

What is this clinical trial studying?

A study testing Coaching, Incentives and Sweetgoals app in people with Type 1 Diabetes, run by Trustees of Dartmouth College at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Aug 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent Glycated Hemoglobin/6 Months (time frame: From Baseline to Month 12). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04646473, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026; AzTrials last refreshed its copy on 29 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in